Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted in order to determine the safety, dose-limiting toxicities, and
maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients
with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)